Literature DB >> 8646408

Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.

S W Castro1, G Buell, W Feniuk, P P Humphrey.   

Abstract

1. The human recombinant somatostatin (SRIF) receptors, sst1 and sst2, have been stably expressed in mouse fibroblast (Ltk-) cells. Two stable clones, LSSR 1/20 and LSSR 11/13, expressing sst1 and sst2 receptors, respectively, have been used to characterize these receptor types using radioligand binding assays as well as measurements of changes in extracellular acidification rates using microphysiometry. 2. [125I]-[Tyr11]-SRIF bound to sst1 and sst2 receptors expressed in Ltk- cells with high affinity, Kd values being 1.52 nM, and 0.23 nM respectively. 3. In Ltk- cells expressing sst1 receptors, SRIF, SRIF-28, [D-Trp8]-SRIF and CGP 23996 all displaced [125I]-[Tyr11]-SRIF binding with high potency (IC50 values of 0.43 - 1.27 nM) whilst seglitide, BIM-23027, BIM-23056 and L-362855 were either weak inhibitors of binding or were ineffective. 4. In contrast MK-678 (seglitide) and BIM-23027 were the most potent inhibitors of [125I]-[Tyr11]-SRIF binding in Ltk- cells expressing sst2 receptors with IC50 values of 0.014 and 0.035 nM, respectively. 5. SRIF and a number of SRIF agonists, including seglitide and BIM-23027, caused concentration-dependent increases in extracellular acidification rates in Ltk- cells expressing sst2 receptors but not in Ltk- cells expressing sst1 receptors. The maximum increase in acidification rate produced by SRIF was 11.3 +/- 0.7% above baseline (0.1-0.28 pH unit min-1). The relative potencies of the SRIF agonists examined in causing increases in extracellular acidification rates in Ltk- cells expressing sst2 receptors correlated well with their relative potencies in inhibiting [125I]-[Tyr11] -SRIF binding (r = 0.94). 6. The increase in extracellular acidification produced by SRIF was markedly inhibited by pretreatment of cells with pertussis toxin (100 ng ml-1) indicating the involvement of pertussis toxin-sensitive G proteins. 7. SRIF (1 microM) had no effect on basal cyclic AMP levels in Ltk- cells expressing sst1 or sst2 receptors nor did it inhibit forskolin stimulated increases in cyclic AMP levels in either cell type. 8. The results from the present study describe the operational characteristics of human sst2 receptors expressed in Ltk- cells where receptor activation causes increases in extracellular acidification rates. This receptor is coupled to a pertussis toxin-sensitive G protein. In contrast, activation of sst1 receptors, at a similar transfection density, did not cause increases in extracellular acidification rates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646408      PMCID: PMC1909325          DOI: 10.1111/j.1476-5381.1996.tb15238.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  The cytosensor microphysiometer: biological applications of silicon technology.

Authors:  H M McConnell; J C Owicki; J W Parce; D L Miller; G T Baxter; H G Wada; S Pitchford
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

2.  Pharmacological properties of two cloned somatostatin receptors.

Authors:  S Rens-Domiano; S F Law; Y Yamada; S Seino; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

3.  Subtypes of brain somatostatin receptors couple to multiple cellular effector systems.

Authors:  K Raynor; H L Wang; M Dichter; T Reisine
Journal:  Mol Pharmacol       Date:  1991-08       Impact factor: 4.436

4.  Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain.

Authors:  K Kaupmann; C Bruns; D Hoyer; K Seuwen; H Lübbert
Journal:  FEBS Lett       Date:  1993-09-27       Impact factor: 4.124

5.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

6.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5.

Authors:  K Raynor; A M O'Carroll; H Kong; K Yasuda; L C Mahan; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

7.  Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.

Authors:  K Raynor; W A Murphy; D H Coy; J E Taylor; J P Moreau; K Yasuda; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

8.  Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase.

Authors:  K Yasuda; S Rens-Domiano; C D Breder; S F Law; C B Saper; T Reisine; G I Bell
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

9.  Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium.

Authors:  W Feniuk; J Dimech; E M Jarvie; P P Humphrey
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

10.  Molecular characterisation, expression and localisation of human neurokinin-3 receptor.

Authors:  G Buell; M F Schulz; S J Arkinstall; K Maury; M Missotten; N Adami; F Talabot; E Kawashima
Journal:  FEBS Lett       Date:  1992-03-24       Impact factor: 4.124

View more
  4 in total

1.  Identification and characterisation of heterogeneous somatostatin binding sites in rat distal colonic mucosa.

Authors:  E S McKeen; W Feniuk; A D Michel; E J Kidd; P P Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Evidence that somatostatin sst2 receptors mediate striatal dopamine release.

Authors:  G J Hathway; P P Humphrey; K M Kendrick
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.

Authors:  Z Szegedi; J Takács; B Szende; Z Vadász; A Horváth; E Gulyás; G Tóth; I Peták; J Bocsi; G Kéri
Journal:  Endocrine       Date:  1999-02       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.